PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has announced positive outcomes from dose range finding studies of its Polycystic Kidney Disease (PKD) drug, PYC-003, in non-human primates, showing safety and potential efficacy. With the drug concentrating effectively in the kidneys, the company is gearing up for human trials in 2024, anticipating clinical data by 2025. The successful development of PYC-003 could address the unmet needs of the 1 in 1,000 people suffering from PKD, representing a significant market opportunity.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
